Tranexamic Acid News and Research

RSS

Early administration of tranexamic acid to patients with severe bleeding injuries saves lives

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

15 Jun 2010

Cheap drug that prevents bleeding may save 100,000 lives each year: Study

Researchers have shown that a cheap and easy to use drug that stops bleeding may save up to 100,000 lives each year from injuries associated with road accidents and violence. The study was published this Tuesday in the acclaimed international journal The Lancet and was conducted by doctors at the London School of Hygiene and Tropical Medicine.

14 Jun 2010

Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA

Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA™ (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

10 May 2010

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

23 Apr 2010

Artificial human skin with dermis made from fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained. This pioneering finding will allow the clinical use of human skin and its use in many laboratory tests on biological tissues -which, additionally, would avoid the use of laboratory animals.

20 Apr 2010

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Risk of death may be higher with aprotinin commonly used during cardiac surgery

The risks of death are probably higher with aprotinin, a drug commonly used to control blood loss and transfusions during cardiac surgery, compared with lysine analogues, according to a study to be published in the January 20th issue of CMAJ.

3 Dec 2008

Anti-fibrinolytics reduce blood loss during cardiac surgery

The amount of blood loss that occurs during major complex surgery is limited by the body's ability to form blood clots.

17 Oct 2007

Fibrin may be new target for Alzheimer's drugs

Despite the rapid rise of Alzheimer's disease - the Alzheimer's Association predicts as many as 7.7 million cases by 2030 - there are no preventative treatments available, few in the pharmaceutical pipeline, and those drugs being developed all share the same two molecular targets.

15 Aug 2007

Aprotinin use associated with an increased risk of death following CABG surgery

Aprotinin, a drug used for limiting blood loss in patients undergoing cardiac surgery, is associated with an increased risk of death during five years following the surgery, according to a new study in the February 7 issue of JAMA: The Journal of the American Medical Association.

7 Feb 2007

Drug used worldwide doubles risk of kidney failure

A drug approved by the FDA, and sold worldwide for the last 13 years, has now been proven to double a patient's risk of kidney failure, and increase the risk of heart attack, heart failure, and stroke.

26 Jan 2006